Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses

Vaccine

Volumn 23, Issue 39, 2005, Pages 4745-4753

  Zanotto, Carlo ^a   Paganini, Manuela ^a   Elli, Veronica ^a   Basavecchia, Valeria ^a   Neri, Margherita ^a   De Guili Morghen, Carlo ^a   Radaelli, Antonia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

AIDS vaccine; Recombinant fowlpox virus; Virus like particles

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MESSENGER RNA; RECOMBINANT VACCINE; RNA DIRECTED DNA POLYMERASE; VIRUS PROTEIN;

ARTICLE; CELL DIVISION; CELL FUSION; CONTROLLED STUDY; FOWLPOX VIRUS; HUMAN; HUMAN CELL; MACACA; MORPHOLOGICAL TRAIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VERO CELL; VIRUS PARTICLE; ANIMAL; CD4+ T LYMPHOCYTE; CERCOPITHECUS; CHEMISTRY; CHICK EMBRYO; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METABOLISM; ULTRASTRUCTURE; VIRION; VIROLOGY; VIRUS ASSEMBLY; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; FOWLPOX VIRUS; HIV; RNA-DIRECTED DNA POLYMERASE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VERO CELLS; VIRAL PROTEINS; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 25144495663     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.05.003     Document Type: Article

References (42)

1. Bojak A, Demi L, Wagner R. The past, present and future of HIV-vaccine development: a critical view. Drug Discov Today 2002;7(1):36-46.
2. Klein M. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine 2001;19:2210-5.
3. Barnett SW, Klinger JM, Doe B, Walker CM, Hansen L, Duliege AM, et al. Prime-boost immunization strategies against HIV. AIDS Res Hum Retroviruses 1998;14(Suppl. 3):299-309.
4. Mascola JR, Nabel GJ. Vaccines for the prevention of HIV-1 disease. Curr Opin Immunol 2001;13:489-95.
5. Wagner R, Shao Y, Wolf H. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine 1999;17:1706-10.
6. Radaelli A, De Giuli Morghen C. Expression of HIV-1 envelope gene by recombinant avipoxvirus. Vaccine 1994;12:1101-9.
7. Salmon-Ceron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI. AIDS Res Hum Retroviruses 1999;15(7):633-45.
8. Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp100 envelope gene. Vaccine 1999;17(17):2166-75.
9. Desrosiers RC. Non human primate models for AIDS vaccines. AIDS 1995;9(Suppl. A): 137-41.
10. Haffar O, Garrigues J, Travis B, Moran P, Zarling J, Hu SL. Human immunodeficiency virus-like particles assemble in a recombinant vaccinia virus expression system. J Virol 1990;64:2653-9.
11. Haglund K, Forman J, Kraeusslich HG, Rose JK. Expression of human immunodeficiency virus type 1 gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 2000;268:112-21.
12. Smith AJ, Cho MI, Hammarskjoeld ML, Rekosh D. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into virus-like particles. J Virol 1990;64:2743-50.
13. Haynes IR, Cao SX, Rovinski B, Sia C, James O, Dekaban GA, et al. Production of immonogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Hum Retroviruses 1991;7(1):17-27.
14. gag virus-like particles by an Epstein-Barr Virus gp220/350-derived transmembrane domain. Virology 1997;235:10-25.
15. Deml L, Schirmbeck R, Reimann I, Wolf H, Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T cells and neutralizing antibodies. Virology 1997;235:26-39.
16. Bonauguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, et al. Induction of neutralizing antibodies and cytotoxic T-lynphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from HIV-1 isolate of clade A. Antiviral Res 2002;54:189-201.
17. Michel ML, Mancini M, Riviere Y, Dormont D, Tiollais P. T- and B-lymphocytes responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/Hepatitis B surface antigen particles. J Virol 1990;64(5):2452-5.
18. Persson RH, Cao SX, Cates G, Yao FL, Klein MH, Rovinski B. Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity. Biologicals 1998;26:255-65.
19. gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 2001;49:35-47.
20. Yao Q, Kuhlmann FM, Eller R, Compans R, Chen C. Production and characterization of simian/human immunodeficiency virus-like particles. AIDS Res Hum Retroviruses 2000;16:227-36.
21. Haddrick M, Han-liu Z, Lau A, Heaphy S, Cann AJ. Production of non-infectious human immunodeficiency virus-like particles which package specifically viral RNA. J Virol Methods 1996;61:89-93.
22. Peters BS, Cheingsong-Popov R, Callow D, Foxall R, Patou G, Hodgkin K, et al. A pilot phase II study of the safety and immunogenicity of HIV p17/p24 VLP (p24-VLP). J Infect 2002;35(3):231-5.
23. Jenkins S, Gritz L, Fedor CH, O'Neill E, Cohen LK, Panicali DL. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res Hum Retroviruses 1991;7:991-7.
24. Kang CY, Luo L, Wainberg MA, Li Y. Development of HIV/AIDS vaccine using chimeri gag-env virus-like particles. Biol Chem 1999;380:353-64.
25. Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HTT, et al. Induction of neutralizing antibodies and Gag-specific cellular immune response to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 2001;75:5879-90.
26. Haffar OK, Smithgall MD, Moran PA, Travis BM, Zarling JM, Hu SL. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. Virology 1991;183(2):487-95.
27. Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particles vaccine in rhesus macaques. AIDS Res Hum Retroviruses 2000;16(3):273-82.
28. Wagner R, Teeuwsen VIP, Demi L, Notka F, Haaksma AGM, Jhagjhoorsingh SS, et al. Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. Virology 1998;245:65-74.
29. Shen L, Mazzara GP, DiSciullo SO, Panicali DL, Letvin NL. Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys. AIDS Res Hum Retroviruses 1993;9:129-32.
30. Notka F, Stahl-Hennig C, Dittmer U, Wolf H, Wagner R. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Biol Chem 1999;380:341-52.
31. Reimann KA, Li IT, Veazey R, Halloran M, Park IW, Karlsson GB, et al. A chimeric Simian/Human Immunodeficiency Virus expressing a primary patient Human Immunodeficiency Virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996;70(10):6922-8.
32. Radaelli A, Zanotto C, Perletti G, Elli V, Vicenzi E, Poli G, et al. Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmid and virus-like particles in prime-boost vaccination protocols against SHIV. Vaccine 2002;21:2052-64.
33. 3HdTTP assay for reverse transcriptase activity. AIDS Research and Reference Reagent Program. Courier 1991;91(2):7.
34. Nermut MV, Zhang WH, Francis G, Ciampor F, Jones IM. Time course of gag protein assembly in HIV-1-infected cells: a study by immuno-electron microscopy. Virology 2003;305:219-27.
35. Jarvis DL, Finn EE. Biochemical analysis of the yV-glycosylation pathway in baculovirus-infected lepidopteran insect cells. Virology 1995;212:500-11.
36. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Corse GJ, Keefer MC, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1(MN) gp120, HIV-1(SF2) recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177(5):1230-46.
37. Shioda T, Shibuta H. Production of Human Immunodeficiency Virus (HIV)-like particles from cells infected with recombinant vaccinia virus carrying the gag gene of HIV. Virology 1990;172:139-48.
38. Rizvi TA, Panganiban AT. Simian Immunodeficiency Virus RNA is efficiently encapsidated by Human Immunodeficiency Virus type 1 particles. J Virol 1993;67:2681-8.
39. Patel J, Wang SW, Izmailova E, Aldovini A. The Simian Immunodeficiency Virus 5′ untranslated leader sequence plays a role in intracellular viral protein accumulation and in RNA packaging. J Virol 2003;77(11):6284-92.
40. Berkowitz RD, Ohagen A, Hoglund S, Goff SP. Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J Virol 1995;69:6445-56.
41. Buseyne F, Le Gall S, Boccaccio C, Abastado J, Lifson JD, Arthur LO, et al. MHC-I restricted presentation of HIV-1 virion antigens without viral replication. Nat Med 2001;7:344-9.
42. Arp J, Rovinski B, Sambhara S, Tartaglia J, Dekaban GA. Human Immunodeficiency Virus type 1 envelope-specific cytotoxic T-lymphocytes response dynamics after prime-boost vaccine regimen with Human Immunodeficiency Virus type 1 canarypox and pseudovirions. Viral Immunol 1999;12(4):281-96.